Key insights
- The post highlights Vivani Medical (VANI), a pre-revenue company developing a slow-release GLP-1 implant. The author suggests VANI could be a takeover target for Eli Lilly or Novo Nordisk, estimating a potential share price of $30. The CEO's recent stock purchases are noted as a positive sign. The GLP-1 market's growth and potential for improved weight loss medications are key drivers. This could positively influence US equity markets, particularly in the biotech and pharmaceutical sectors.
Hi stocks and stonks bros (&Gals)
I might have found it, simply put, the little gem that’s pre revenue but based on my current straight up knowledge of how the GLP-1 market is growing at such an astronomical rate that anything touching this sector is bound to fly.
Vivani medical inc:VANI
This is a no waffle post, ask me questions and I’m
Happy to answer.
Simply put, nano slow release GLP-1 implant, 50% of Americans have known to miss their weekly shot which is a huge statistic which is not great for weight loss analysis.
It’s a 1Trillion dollar industry by the end of 2028
A few things, Vivani will look implement this with the new GLP medication coming out from Eli Lilly (those that know about it I don’t need to mention the name), with even better fat loss results, fatty liver reduction and further decrease in muscle wasting and osteoporosis side effects.
A buy out from Eli or Novo puts this stock at around $30 a share
Lastly. The CEO has been buying bundles of $2,000,000 over the last 12 months.
I personally dropped €6,340 today, a dent in the ocean, see you in Valhalla or behind the back of Wendy’s.
Happy investing. NFA.